Drugs / DS-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04598295 | Oct 2020 → Oct 2022 | irritable bowel syndrome | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04598295 ↗ |
| Modality | Other / unclassified | “DS-01 is a rationally defined microbial consortia consisting of 24 strains across 12 species” NCT04598295 ↗ |
| Route | Oral | “Participants will be instructed to take 2 capsules daily for the duration of the trial.” NCT04598295 ↗ |